Aida Pharmaceuticals announced that its Shanghai Qiaer subsidiary is working on a second cancer drug, called Vasostatin-Apo2L. The compound is in pre-clinical development. It builds on the previously announced Shanghai Qiaer cancer drug, Rh-Apo2L, which causes apoptosis or cell death. Rh-Apo2L has completed Phase II clinical testing; it will file an application with the SFDA to begin a Phase III trial. More details..

Stock Symbol: (OTCBB: AIDA)